In recent years, RPPA has been utilized for profiling breast cancers [10], endometrioid and clear cell carcinomas [11] head and neck squamous cell carcinoma (HNSCC) patient derived xenografts, [12] studying mTOR activation in sorafenib-resistant hepatocellular carcinoma (HCC) [13], for biomarker discovery [14], characterization of signaling pathways [15] and for distinguishing different cancers [16]. Here, MTOR is linked to hepatocellular carcinoma.